Modeling effective doses of therapeutic antibodies targeting clustered surface receptors
Discover how semi-mechanistic PK/receptor-occupancy modeling reveals that lower, subcutaneous doses, not maximum tolerated doses, optimize…
Danielle PillsburySeptember 23, 2026
Model-Informed Strategies for ADC Development
Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…
Danielle PillsburySeptember 22, 2026
Semi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers
A semi-mechanistic population PK model characterizes sorfequiline and its active M3 metabolite to support DDI…
CertaraSeptember 18, 2026
Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy
Pharmacometric modeling of givinostat in pediatric DMD supported a simplified 4-band weight-based dosing regimen without…
CertaraSeptember 14, 2026
Beyond Simple Allometric Scaling: Why Time-Course Methods Win for First-in-Human Predictions
Simple allometric scaling stops at clearance and volume. See how Dedrick plots and the Wajima…
Danielle PillsburySeptember 11, 2026
From Sentence to Simulation: Bringing AI Assistance to Pharmacometrics Modeling
Describe pharmacometric models in natural language and let AI write ready-to-run NLME code. See the…
Arjen BosSeptember 1, 2026
A glimpse into the future of model-informed drug discovery and development
Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…
CertaraAugust 28, 2026
